Neurocrine Biosciences, Inc. (NBIX) Shareholders & Insider Trades
Neurocrine Biosciences shareholders at a glance
The largest holder of Neurocrine Biosciences stock is BlackRock Advisors LLC, with 11.9 million shares (11.66% of the company), worth about $1.83 billion as of September 25, 2026. The 10 largest holders together own 47.3%.
In Q2 2026, 808 institutional holdings reports listed shares worth $17.20 billion.
Insiders reported 96 transactions in the last two years: 26 sales worth $48.16 million and no purchases. The newest one on file is from May 12, 2026 (Norwalk Leslie V, Director).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 12, 2026.
Neurocrine Biosciences, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Neurocrine Biosciences shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| BlackRock Advisors LLC | 11.9 million | 11.66% | $1.8B |
| JPMorgan Investment Management, Inc. | 6.4 million | 6.29% | $986.0M |
| Dodge & Cox | 5.6 million | 5.49% | $860.0M |
| Vanguard Portfolio Management LLC | 5.0 million | 4.89% | $766.0M |
| Vanguard Capital Management LLC | 4.5 million | 4.47% | $700.0M |
| State Street Corporation | 4.4 million | 4.31% | $676.0M |
| AQR Capital Management LLC | 3.8 million | 3.76% | $588.0M |
| Renaissance Technologies LLC | 2.3 million | 2.30% | $360.0M |
| Geode Capital Management LLC | 2.1 million | 2.10% | $329.0M |
| Two Sigma Investments LP | 2.1 million | 2.04% | $320.0M |
As of September 25, 2026.
Neurocrine Biosciences institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 808 | – | $17.2B |
| Q1 2026 | 720 | 100.0 million | $13.2B |
| Q4 2025 | 759 | 99.3 million | $14.1B |
| Q3 2025 | 674 | 102.0 million | $14.3B |
| Q2 2025 | 610 | 99.2 million | $12.5B |
| Q1 2025 | 610 | 96.7 million | $10.7B |
| Q4 2024 | 629 | 94.8 million | $12.9B |
| Q3 2024 | 609 | 95.2 million | $11.0B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Neurocrine Biosciences insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Norwalk Leslie V | May 12, 2026 | Director | Sale at price 155.01 per share. | $590,601 |
| Abernethy Matthew C | Mar 4, 2026 | Chief Financial Officer | Stock Gift at price 0.00 per share. | – |
| Onyia Jude | Feb 20, 2026 | Officer | Stock Gift at price 0.00 per share. | – |
| Lippoldt Darin M | Feb 13, 2026 | Officer | Stock Gift at price 0.00 per share. | – |
| Gorman Kevin Charles | Feb 13, 2026 | Director | -- | – |
| Lippoldt Darin M | Feb 13, 2026 | Officer | -- | – |
| Gano Kyle W | Feb 13, 2026 | Chief Executive Officer | -- | – |
| Benevich Eric S. | Feb 13, 2026 | Officer | -- | – |
| Abernethy Matthew C | Feb 13, 2026 | Chief Financial Officer | -- | – |
| Cooke Julie Smith | Feb 13, 2026 | Officer | -- | – |
| Boyer David Warren | Feb 13, 2026 | Officer | -- | – |
| Onyia Jude | Feb 13, 2026 | Officer | -- | – |
Newest 12 of 96 insider transactions in the last two years.
Questions and answers
Who owns the most Neurocrine Biosciences stock?
BlackRock Advisors LLC, with 11.66% of the company (as of September 25, 2026). Next: JPMorgan Investment Management, Inc. (6.29%) and Dodge & Cox (5.49%).
How many institutions own Neurocrine Biosciences stock?
808 institutional holdings reports listed Neurocrine Biosciences shares in Q2 2026 worth $17.20 billion.
Are Neurocrine Biosciences insiders buying or selling the stock?
In the last two years insiders reported 26 sales and no purchases (96 transactions in all); the newest on file is from May 12, 2026.
